Novavax, Inc. (NASDAQ:NVAX) shares are trading higher by 8.4% at $242.67 on continued strength after the company on Wednesday announced an agreement with the European Commission for the purchase of up to 200 million doses of its COVID-19 vaccine.
Novavax shares are trading higher by 32.5% over the past five sessions amid ongoing COVID-19 delta variant concerns, which have lifted vaccine stocks.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly-owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.
Novavax has a 52-week high of $331.68 and a 52-week low of $76.59.
